



## BioCryst to Present at Two Upcoming Investor Conferences

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- [BioCryst Pharmaceuticals, Inc.](http://www.BioCryst.com) (NASDAQ: BCRX) today announced that executives from BioCryst are scheduled to present and provide a corporate summary and update regarding the Company's clinical programs at the following investor conferences:

- Cowen & Co. 32<sup>nd</sup> Annual Healthcare Conference in Boston, Massachusetts on Monday, March 5, 2012 at 4:50 p.m. Eastern time
- Roth Capital 24<sup>th</sup> Annual Growth Stock Conference in Dana Point, California on Wednesday, March 14, 2012 at 1:30 p.m. Pacific Time

Links to live audio webcasts and replays of both presentations may be accessed on the BioCryst website at [www.BioCryst.com](http://www.BioCryst.com).

### About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals designs, optimizes and develops novel small-molecule pharmaceuticals that block key enzymes involved in infectious diseases, inflammatory diseases and cancer. BioCryst currently has three novel late-stage compounds in development: peramivir, a neuraminidase inhibitor for the treatment of influenza, BCX4208, a purine nucleoside phosphorylase (PNP) inhibitor for the treatment of gout, and forodesine, an orally-available PNP inhibitor for cancer, which is being developed by Mundipharma under a global license agreement. Utilizing crystallography and structure-guided drug design, BioCryst continues to discover additional compounds and to progress others through preclinical and early development to address the unmet medical needs of patients and physicians. For more information, please visit the Company's website at [www.BioCryst.com](http://www.BioCryst.com).

This press release contains forward-looking statements, including statements regarding future results and achievements. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. Please refer to the documents BioCryst files periodically with the SEC and located at <http://investor.shareholder.com/biocryst/sec.cfm>.

BCRXW

BioCryst Pharmaceuticals  
Robert Bennett, 919-859-7910

Source: BioCryst Pharmaceuticals

News Provided by Acquire Media